Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): clinical problems
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Goldin (Santa Monica, United States of America). QLF change is more sensitive than FVC change in predicting Progression Free survival (PFS) in IPF trials. 1958

Member's Comments

No comment yet.

Related content which might interest you: Short term Quantitative Lung Fibrosis (QLF) change predicts rapid rate of FVC decline in patients with IPF Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Percent predicted forced vital capacity (FVC) is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - Clinical issues in idiopathic pulmonary fibrosis Year: 2010 Clinical and biological predictors of progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated by erlotinib in the ERMETIC cohort Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 Automatic quantitative fibrosis scores at baseline is a predictor of progression in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): clinical problems Year: 2017 Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 The importance of the disease-free survival (DFS) endpoint to survivors of lung cancer Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Do worse scores on patient-reported outcomes predict the progression of interstitial lung disease (ILD)? Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Multicomponent indices to predict survival in COPD: the COCOMICS study Source: Eur Respir J 2013; 42: 323-332 Year: 2013 Improved survival with increased IC/TLC ratio, DLCO and FEV1 in an analysis of a COPD pulmonary function database Source: Annual Congress 2011 - Lung and airway function Year: 2011 Multicomponent indices to predict survival in COPD Source: Eur Respir J 2014; 43: 1206 Year: 2014 Multicomponent indices to predict survival in COPD Source: Eur Respir J 2014; 43: 1207 Year: 2014 Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 The incremental shuttle walk test (ISW) in patients with bronchiectasis: Response to pulmonary rehabilitation (PR) and minimum clinically important difference (MCID) Source: International Congress 2019 – Hot topics in pulmonary rehabilitation Year: 2019 Annual rate of FVC decline in patients with IPF treated with pirfenidone: Pooled analysis from 3 pivotal studies Source: International Congress 2016 – IPF treatment I Year: 2016 Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry. Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 Novel patterns of serum biomarkers profiling using minimal important clinical outcomes (MICO) in the longidutinal study BODE cohort of COPD patients Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010 Impact of baseline desaturation during a six minute walk test (6MWT) on prognostic value of subsequent changes in FVC and DLCO Source: Eur Respir J 2006; 28: Suppl. 50, 828s Year: 2006 Early changes in eDiary COPD symptoms predict trough FEV1 and TDI responders at 12 weeks in the CRYSTAL trial Source: International Congress 2017 – Management of COPD Year: 2017 Predicting IPF outcomes: lung function evaluation by %predicted and z-score Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021